DIABETES TYPE 1.5 An endocrinologist diagnosed my patient with type 1.5 diabetes during hospitalization
Often referred to as skinny shots, these medications have become a hot topic among those seeking effective weight loss solutions
Many users look to it for connective-tissue support, such as tendons and ligaments, where healing can be slow due to limited blood supply
Synthesis of the acid-labile subunit of the growth-hormone-dependent insulin-like-growth-factor-binding protein complex by rat hepatocytes in culture
The current generation of GLP-1 receptor agonists includes: Semaglutide (weekly subcutaneous injection or oral formulation) Liraglutide (daily subcutaneous injection) Tirzepatide (dual GLP-1/GIP receptor agonist, weekly subcutaneous injection) Each of these GLP-1 agents carries a distinct pharmacological profile, and the optimal choice depends on a patients clinical history, metabolic risk factors, and therapeutic goals a determination best made in consultation with a physician experienced in metabolic and longevity medicine
As new therapies emerge, clinicians face a critical question: which modern therapy offers the best outcomesGLP-1 agonists or SGLT2 inhibitors